Impact of Infliximab Biosimilar (Ixifi®) Trough Levels on Disease Activity and Inflammatory Markers in Iraqi Rheumatoid Arthritis Patients
DOI:
https://doi.org/10.54133/ajms.v7i1(Special).906Keywords:
Biosimilar, Iraqi patients, Ixifi®, Rheumatoid arthritisAbstract
Background: Rheumatoid arthritis is an autoimmune inflammatory condition that impacts the small and larger joints. Ixifi® is a biosimilar medication derived from infliximab that exclusively targets Tumor Necrosis Factor-α. Serum Ixifi® trough concentration is necessary to manage disease activity in rheumatoid arthritis. Objective: Assess the impact of the Ixifi® trough level on disease activity and inflammatory biomarkers. Methods: A cross-sectional observational study was undertaken at Baghdad Teaching Hospital, involving forty-two patients diagnosed with rheumatoid arthritis according to ACR/EULAR 2010 criteria. After 3 months after initiating therapy with Ixifi®, the serum concentrations of Ixifi®, as well as CDAI, ESR, and CRP biomarkers, were measured. Results: After 3 months of therapy with Ixifi®, the patients in the remission group had a higher concentration of Ixifi® compared to the mild, moderate, and severe disease activity groups. Ixifi® trough level in remission was 5.45 µg/ml, while in mild, moderate, and severe groups, it was 3.575 µg/ml, 2.2 µg/ml, and 0.66 µg/ml, respectively. The CDAI scores were in the severe group (26.0), moderate group (19.0), mild group (7.0), and remission group (2.0). Furthermore, the findings indicate an inverse correlation between the Ixifi® trough level and both ESR and CRP. Conclusions: A drop in Ixifi® levels leads to an increase in disease severity and inflammation, while high concentrations of Ixifi® decrease disease activity, ESR, and CRP.
Downloads
References
Mohammed AM, Zayni SM, AL-Anee MM, Corial FI, Rubaee AA. Diagnostic and predictive values of IL-6 in a group of Iraqi patients with rheumatoid arthritis. J Fac Med Baghdad. 2023;65(2). doi: 10.32007/jfacmedbagdad.2044.
Oglah AA, Mohammed KIA, Alosami MH. A comparative study of serum amyloid A2 with anti-cyclic citrullinated peptide antibody in the prognosis of a group of rheumatoid arthritis patients in Iraq. J Fac Med Baghdad. 2022;64(3):153-158. doi: 10.32007/jfacmedbagdad.6431947.
Bilal M, Qindeel M, Nunes LV, Duarte MTS, Ferreira LFR, Soriano RN, et al. Marine-derived biologically active compounds for the potential treatment of rheumatoid arthritis. Mar Drugs. 2020;19(1):10. doi: 10.3390/md19010010.
Al-Rawi ZS, Alazzawi AJ, Alajili FM, Alwakil R. Rheumatoid arthritis in population samples in Iraq. Ann Rheum Dis. 1978;37(1):73-75. doi: 10.1136/ard.37.1.73.
Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020;110:102400. doi: 10.1016/j.jaut.2019.102400.
Abbas NR, Obeidy ESA, Naim SNA, Kadim AE. Correlation between some immunological parameters and clinical presentation in RA patients. J Fac Med Baghdad. 2008;50(2):235-240. doi: 10.32007/jfacmedbagdad.5021288.
Abdul-Qahar ZH, Mahmood HG, Rasheed MK. Measurement of anti-cyclic citrullinated peptide, leptin hormone, and lipoprotein (a) in Iraqi female patients with rheumatoid arthritis. J Fac Med Baghdad. 2014;56(3):305-307. doi: 10.32007/jfacmedbagdad.563507.
Mohammed AH, Al-Khedairy EBH. Formulation and in vitro evaluation of taste- masked prednisolone orodispersible tablets. J Fac Med Baghdad. 2023;65(3):192-198. doi: 10.32007/jfacmedbagdad.2057.
Albarzinji NJ. The efficacy of infliximab plus methotrexate in patients with active rheumatoid arthritis in North of Iraq: 5 year extended study. Adv Med J. 2018;4(1):6-10. doi: 10.56056/amj.2018.33.
McClellan JE, Conlon HD, Bolt MW, Kalfayan V, Palaparthy R, Rehman MI, et al. The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. Ther Adv Gastroenterol. 2019;12:1756284819852535. doi: 10.1177/1756284819852535.
Al-Salama ZT. PF-06438179/GP1111: An Infliximab Biosimilar. BioDrugs Clin Immunother Biopharm Gene Ther. 2018 Dec;32(6):639-42. doi: 10.1007/s40259-018-0310-5.
Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology (ACR) - European League Against Rheumatism (EULAR) criteria for minimal, moderate and major clinical response for juvenile dermatomyositis: An international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis. 2017;76(5):782-791. doi: 10.1002/art.40060.
Salaffi F, Di Carlo M, Farah S, Marotto D, Atzeni F, Sarzi-Puttini P. Rheumatoid arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. Acta Biomed. 2021;92(4):e2021238. doi: 10.23750/abm.v92i4.10831.
Gorial FI. Validity and reliability of CDAI in comparison to DAS28 in Iraqi patients with active rheumatoid arthritis. J Fac Med Baghdad. 2012;54(3):231. doi: 10.32007/jfacmedbagdad.543724.
Koh JH, Lee Y, Kim HA, Kim J, Shin K. Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry. Ther Adv Musculoskelet Dis. 2022;14:1759720X221096363. doi: 10.1177/1759720X221096363.
Plasencia C, Jurado T, Villalba A, Peitedado D, Casla MTL, Nuño L, et al. Effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: A cohort study in clinical practice conditions. Front Med. 2015;2:71. doi: 10.3389/fmed.2015.00071.
Teresa J, Chamaida PR, Ana MF, Victoria NC, Theo R, Annick V, et al. Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients. Open Rheumatol J. 2017;11:75-87. doi: 10.2174/1874312901711010075.
Al-Karkhi MA, Al-Ani MM, Jassim NA. Development of anti-bodies against infliximab in Iraqi patients with rheumatoid arthritis. J Fac Med Baghdad. 2015;57(3):241-243. doi: 10.32007/jfacmedbagdad.573372.
Fleischmann RM, van der Heijde D, Gardiner PV, Szumski A, Marshall L, Bananis E. DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open. 2017;3(1):e000382. doi: 10.1136/rmdopen-2016-000382.
Nair A, Pruthi P, Marwaha V, Surendran S, Tiwari A, Mathew AR. Assessment of disease activity in rheumatoid arthritis: A comparative study of clinical and laboratory evaluation with musculoskeletal ultrasonography assessment. J Assoc Physicians India. 2022;70(2):11-12. PMID: 35436826.
Al-Hassan AAH. Role of pro- and anti-inflammatory cytokines in rheumatoid arthritis: Correlation with disease activity. J Fac Med Baghdad. 2010 ;52(3):286-291. doi: 10.32007/jfacmedbagdad.523976.
Tutan D, Doğan AG. Pan-immune-inflammation index as a biomarker for rheumatoid arthritis progression and diagnosis. Cureus. 2023;15(10):e46609. doi: 10.7759/cureus.46609.
Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806. doi: 10.1186/ar1740.
Thanoon IA, Tawfik NO, Hussin FN. Oxidative stress & C-reactive protein in patients with arthritis. J Fac Med Baghdad. 2007;49(2):227-230.
Scali JJ, Visentini S, Salomón J, Sevilla D, Ju YC, Morales E, et al. Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants. Ann N Y Acad Sci. 2007;1110:389-401. doi: 10.1196/annals.1423.041.
Valor L, Hernández-Flórez D, de la Torre I, Del Río T, Nieto JC, González C, et al. Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients. Clin Exp Rheumatol. 2015;33(6):805-811. PMID: 26314759.
Shakir MJ, Hussein AA. Assessment of serum interleukin-2, -4 and C-reactive protein levels in patients with giardiasis and cryptosporidiosis. J Fac Med Baghdad. 2014;56(3):313-317. doi: 10.32007/jfacmedbagdad.563516.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).